Optimization of a novel chelerythrine-loaded magnetic Fe3 O4 /chitosan alpha-ketoglutaric acid system and evaluation of its anti-tumour activities.

Fei Yang,Wen Xiao,Xiaohua Ma,Ruixue Huang,Ran Yu,Guiyin Li,Xiao Huang,Cuimei Chen,Ping Ding
DOI: https://doi.org/10.1111/jphp.12564
2016-01-01
Journal of Pharmacy and Pharmacology
Abstract:ObjectivesA novel magnetic targeting anti-tumour drug delivery system (Fe3O4/KCTS-CHE) was designed using magnetic Fe3O4/chitosan alpha-ketoglutaric acid (Fe3O4/KCTS) as carrier and chelerythrine (CHE) as an anti-tumour drug model. Moreover, the anti-tumour activities and mechanisms of Fe3O4/KCTS-CHE were investigated. MethodsThe preparation conditions of Fe3O4/KCTS-CHE microspheres were optimized by response surface methodology (RSM). The CHE drug release kinetics was evaluated by fitting the experimental data to standard release equations. The inhibitive activities of Fe3O4/KCTS-CHE microspheres against the HepG2 cells were estimated using MTT assay in vitro, and the mechanisms were studied using Hoechst 33258 staining. Key findingsThe optimum preparation conditions were 11.68 : 1 for Fe3O4/KCTS:CHE ratio, 4 : 1 for oil/water ratio and 50.03 min for the ultrasonic time. The drug loading content and entrapment efficiency under the optimal conditions were 23.3% and 50.9%. The best fit was Higuchi model for the microspheres. The inhibitive rate on HepG2 cells of Fe3O4/KCTS-CHE nanoparticles varied from 30.19 2.64% to 70.46 +/- 6.42% at different concentrations from 50 to 400 mg/l in 72 h. ConclusionFe(3)O(4)/KCTS-CHE exhibited effective anti-tumour activities against the HepG2 cells and induced cell apoptosis in HepG2 cells. Fe3O4/KCTS-CHE possess a high drug loading efficiency and entrapment efficiency, which are a new matrix for controlling release of drugs and a promising candidate for targeted drug delivery.
What problem does this paper attempt to address?